Prosecution Insights
Last updated: April 19, 2026
Application No. 17/917,450

COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

Final Rejection §DP
Filed
Oct 06, 2022
Examiner
SCHMIDT, IZABELA MARIA
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ptc Therapeutics Inc.
OA Round
2 (Final)
62%
Grant Probability
Moderate
3-4
OA Rounds
3y 0m
To Grant
99%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allow Rate
49 granted / 79 resolved
+2.0% vs TC avg
Strong +53% interview lift
Without
With
+53.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
39 currently pending
Career history
118
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
31.5%
-8.5% vs TC avg
§102
19.7%
-20.3% vs TC avg
§112
18.1%
-21.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 79 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . FINAL REJECTION Priority Instant application 17/917,450 filed on 10/06/2022 claims benefit as follow: CONTINUING DATA: PNG media_image1.png 49 339 media_image1.png Greyscale Status of the Application Claims 1-9, 15-16, 19, 22, 26-28 and 76 are pending. Response to Arguments/Amendments The amendment filled on 11/25/2025 has been entered. Regarding objections to specification, Applicant’s amendment has overcome the objection. Thus, the objection is withdrawn. Regarding 112(b) rejection, Applicant’s amendment has overcome the rejection. Thus, the rejection is withdrawn. Regarding 102 rejection, Applicant’s amendment has overcome the rejection. Thus, the rejection is withdrawn. Regarding double patenting rejection over 18/211,134, since the ‘134 Application is abandoned, the double patenting rejection over 18/211,134 is withdrawn. Regarding double patenting rejection over 17/610,617, Applicant requested that this double patenting rejection is held in abeyance. Since no arguments are present, the double patenting rejection over 17/610,617 is maintained. Election/Restrictions Claim 76 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 07/14/2025. Regarding species election, Applicant elected compound 1 PNG media_image2.png 288 129 media_image2.png Greyscale in the reply filed on 07/14/2025. PNG media_image3.png 204 607 media_image3.png Greyscale Claims 3, 4 and 16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 07/14/2025. Examination will begin with the elected species. In accordance with the MPEP 803.02, if upon examination of the elected species, no prior art is found that would anticipate or render obvious the instant invention based on the elected species, the search of the Markush-type claim will be extended. If prior art is then found that anticipates or renders obvious the non-elected species, the Markush-type claim will be rejected. It should be noted that the prior art search will not be extended unnecessarily to cover all non-elected species. Should Applicant overcome the rejection by amending the claim, the amended claim will be reexamined. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. In the event prior art is found during reexamination that renders obvious or anticipates the amended Markush-type claim, the claim will be rejected and the action made final. As per MPEP 803.02, the Examiner will attempt to determine whether the entire scope of the claims is patentable. Applicants' elected species, as shown above, does make a contribution over the prior art. Therefore, according to MPEP 803.02: should the elected species appear allowable; the search of the Markush-type claim will be extended. The search and examination should be continued until either (1) prior art is found that anticipates or renders obvious a species that falls within the scope of a proper Markush grouping that includes the elected species, or (2) it is determined that no prior art rejection of any species that falls within the scope of a proper Markush grouping that includes the elected species can be made. The Examiner need not extend the search beyond a proper Markush grouping. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 1-2, 5-9, 19, 22 and 26 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9, 13-14 and 19-23 of copending Application No. 17/610,617 (notice of allowance mailed 11/12/2025). Claims of Application No. 17/610,617 recite a compound of Formula (I) and Formula (III): PNG media_image4.png 441 717 media_image4.png Greyscale The compounds of Formula (III) recited in Application No. 17/610,617 are positional isomers of compounds of Formula (I) recited in the instant claims wherein X is N. The compounds differ in the position of triazine ring. However, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to prepare isomers of compounds of Formula (III). MPEP 2144.09 states: “Compounds which are position isomers (compounds having the same radicals in physically different positions on the same nucleus) or homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties”. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: The closes prior art of record is SYDORENKO (WO2019191229). SYDORENKO teaches: PNG media_image5.png 221 682 media_image5.png Greyscale For example, SYDORENKO discloses compound 262, 263, 328 and 116: PNG media_image6.png 252 92 media_image6.png Greyscale PNG media_image7.png 268 90 media_image7.png Greyscale PNG media_image8.png 250 96 media_image8.png Greyscale PNG media_image9.png 259 89 media_image9.png Greyscale However, SYDORENKO does not disclose the specific compounds recited in instant claims 27 and 28. Without suggestion from prior art, one of ordinary skill would have not been motivated to arrive at the instant, specific compounds with a reasonable expectation of success. Further, regarding instant claim 15, the compounds of instant claim 1 differ at least in a position corresponding to instant A variable. Without suggestion from prior art, one of ordinary skill would have not been motivated to arrive at the instant compounds of formula (I) wherein X is CH with a reasonable expectation of success. Conclusion Claims 15, 27 and 28 are allowed. Claims 1-2, 5-9, 19, 22 and 26 are rejected. Claims 3, 4, 16 and 76 are withdrawn. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to IZABELA SCHMIDT whose telephone number is (703)756-4787. The examiner can normally be reached Monday - Friday from 9 am to 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /I.S./Examiner, Art Unit 1621 /CLINTON A BROOKS/Supervisory Patent Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Oct 06, 2022
Application Filed
Aug 26, 2025
Non-Final Rejection — §DP
Nov 25, 2025
Response Filed
Dec 31, 2025
Final Rejection — §DP
Apr 06, 2026
Request for Continued Examination
Apr 07, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582654
CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12569502
USE OF BILE ACIDS AND DERIVATIVES THEREOF IN PREPARATION OF GPR39 AGONIST
2y 5m to grant Granted Mar 10, 2026
Patent 12552796
EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12544376
AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF
2y 5m to grant Granted Feb 10, 2026
Patent 12544385
COMBINATION DRUG THERAPIES FOR CNS DISORDERS
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
62%
Grant Probability
99%
With Interview (+53.3%)
3y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 79 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month